Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Generation Bio (GBIO) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Generation Bio (GBIO) over the last 5 years, with Q3 2025 value amounting to $400000.0.

  • Generation Bio's Other Accumulated Expenses fell 123.46% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 123.46%. This contributed to the annual value of $2.7 million for FY2024, which is 55467.98% up from last year.
  • Per Generation Bio's latest filing, its Other Accumulated Expenses stood at $400000.0 for Q3 2025, which was down 123.46% from $462000.0 recorded in Q2 2025.
  • In the past 5 years, Generation Bio's Other Accumulated Expenses registered a high of $2.7 million during Q4 2024, and its lowest value of $282000.0 during Q2 2022.
  • In the last 5 years, Generation Bio's Other Accumulated Expenses had a median value of $426000.0 in 2022 and averaged $691263.2.
  • Per our database at Business Quant, Generation Bio's Other Accumulated Expenses crashed by 7684.73% in 2022 and then surged by 55467.98% in 2024.
  • Quarter analysis of 5 years shows Generation Bio's Other Accumulated Expenses stood at $676000.0 in 2021, then plummeted by 36.98% to $426000.0 in 2022, then decreased by 4.69% to $406000.0 in 2023, then skyrocketed by 554.68% to $2.7 million in 2024, then crashed by 84.95% to $400000.0 in 2025.
  • Its Other Accumulated Expenses was $400000.0 in Q3 2025, compared to $462000.0 in Q2 2025 and $1.5 million in Q1 2025.